Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Guyer Charles Greg | Nov 12, 2024 | Sell | 5,278 | $66.3743 | $350,000 |
| Burkhart Erin | Aug 13, 2024 | Sell | 714 | $90 | $64,000 |
| Mueller Brian | May 30, 2024 | Sell | 5,000 | $75.19 | $380,000 |
| Davis George Eric | May 28, 2024 | Sell | 38,071 | $74.455 | $2.8M |
| Davis George Eric | May 28, 2024 | Sell | 2,779 | $75.288 | $210,000 |
| BIENAIME JEAN JACQUES | May 10, 2024 | Sell | 20,000 | $81.14 | $1.6M |
| Davis George Eric | May 2, 2024 | Sell | 1,850 | $85.01 | $160,000 |
| Ajer Jeffrey Robert | May 2, 2024 | Sell | 5,000 | $82.91 | $410,000 |
| BIENAIME JEAN JACQUES | Apr 12, 2024 | Sell | 20,000 | $91.26 | $1.8M |
| Burkhart Erin | Apr 10, 2024 | Sell | 2,286 | $90 | $210,000 |
| Davis George Eric | Mar 28, 2024 | Sell | 24,602 | $88.34 | $2.2M |
| BIENAIME JEAN JACQUES | Mar 6, 2024 | Sell | 1,000 | $86.713 | $87,000 |
| FUCHS HENRY J | Mar 5, 2024 | Sell | 35,341 | $85.1814 | $3M |
| Ajer Jeffrey Robert | Mar 5, 2024 | Sell | 4,000 | $87.07 | $350,000 |
| BIENAIME JEAN JACQUES | Feb 27, 2024 | Sell | 1,000 | $90.35 | $90,000 |
| BIENAIME JEAN JACQUES | Feb 9, 2024 | Sell | 15,000 | $88.28 | $1.3M |
| BIENAIME JEAN JACQUES | Jan 10, 2024 | Sell | 10,000 | $96.38 | $960,000 |
| BIENAIME JEAN JACQUES | Dec 21, 2023 | Sell | 10,000 | $93.99 | $940,000 |
| Davis George Eric | Dec 13, 2023 | Sell | 13,764 | $95.3 | $1.3M |
| Ajer Jeffrey Robert | Aug 16, 2023 | Sell | 5,000 | $90 | $450,000 |
| FUCHS HENRY J | Aug 10, 2023 | Sell | 12,000 | $90.4259 | $1.1M |
| Guyer Charles Greg | Aug 9, 2023 | Sell | 5,360 | $93.304 | $500,000 |
| Davis George Eric | Aug 8, 2023 | Sell | 11,000 | $89.4238 | $980,000 |
| BIENAIME JEAN JACQUES | Aug 8, 2023 | Sell | 6,000 | $88.29 | $530,000 |
| BIENAIME JEAN JACQUES | Aug 7, 2023 | Sell | 4,000 | $88.1 | $350,000 |
| BIENAIME JEAN JACQUES | May 11, 2023 | Sell | 24,439 | $94.55 | $2.3M |
| BIENAIME JEAN JACQUES | May 11, 2023 | Sell | 5,561 | $95.22 | $530,000 |
| BIENAIME JEAN JACQUES | May 10, 2023 | Sell | 21,453 | $94.65 | $2M |
| BIENAIME JEAN JACQUES | May 10, 2023 | Sell | 8,547 | $95.34 | $810,000 |
| BIENAIME JEAN JACQUES | May 9, 2023 | Sell | 14,964 | $95.49 | $1.4M |
| BIENAIME JEAN JACQUES | May 9, 2023 | Sell | 13,626 | $94.22 | $1.3M |
| BIENAIME JEAN JACQUES | May 9, 2023 | Sell | 1,410 | $95.9 | $140,000 |
| BIENAIME JEAN JACQUES | Apr 10, 2023 | Sell | 10,000 | $99.56 | $1,000,000 |
| BIENAIME JEAN JACQUES | Apr 6, 2023 | Sell | 10,000 | $96.13 | $960,000 |
| LAWLIS V BRYAN | Apr 3, 2023 | Sell | 8,500 | $97.09 | $830,000 |
| BIENAIME JEAN JACQUES | Mar 13, 2023 | Sell | 8,000 | $90.45 | $720,000 |
| BIENAIME JEAN JACQUES | Mar 10, 2023 | Sell | 15,000 | $92.28 | $1.4M |
| BIENAIME JEAN JACQUES | Feb 13, 2023 | Sell | 6,000 | $109.15 | $650,000 |
| BIENAIME JEAN JACQUES | Feb 10, 2023 | Sell | 15,000 | $110.11 | $1.7M |
| Ajer Jeffrey Robert | Jan 25, 2023 | Sell | 44,825 | $115.654 | $5.2M |
| Ajer Jeffrey Robert | Jan 25, 2023 | Sell | 4,175 | $116.154 | $480,000 |
| BIENAIME JEAN JACQUES | Jan 17, 2023 | Sell | 10,000 | $111.55 | $1.1M |
| Mueller Brian | Jan 13, 2023 | Sell | 2,500 | $114.5 | $290,000 |
What's the latest insider transaction for Biomarin Pharmaceutical?
The most recent insider transaction for Biomarin Pharmaceutical was conducted by Guyer Charles Greg, who sold 5,278 shares on November 12, 2024 at a price of $66.37 per share.
Which insider has sold the most BMRN stock over the last two years?
BIENAIME JEAN JACQUES has sold the most BMRN stock in the last 2 years, with a total value of $24M.
What is the total value of insider transactions for Biomarin Pharmaceutical (BMRN) in the last 2 years?
The total value of insider transactions for Biomarin Pharmaceutical in the last 2 years is negative, amounting to -$45M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Biomarin Pharmaceutical's market confidence?
Over the last 2 years, insider transactions for Biomarin Pharmaceutical have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
